You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
| Title |
Efficacy and safety of 8 weeks versus 12 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin in patients with hepatitis C virus genotype 1 mono-infection and HIV/hepatitis C virus co-infection (C-WORTHY): a randomised, open-label phase 2 trial
|
|---|---|
| Published in |
The Lancet, November 2014
|
| DOI | 10.1016/s0140-6736(14)61793-1 |
| Pubmed ID | |
| Authors |
Mark Sulkowski, Christophe Hezode, Jan Gerstoft, John M Vierling, Josep Mallolas, Stanislas Pol, Marcelo Kugelmas, Abel Murillo, Nina Weis, Ronald Nahass, Oren Shibolet, Lawrence Serfaty, Marc Bourliere, Edwin DeJesus, Eli Zuckerman, Frank Dutko, Melissa Shaughnessy, Peggy Hwang, Anita Y M Howe, Janice Wahl, Michael Robertson, Eliav Barr, Barbara Haber |
| Abstract |
Both hepatitis C virus (HCV) mono-infected and HIV/HCV co-infected patients are in need of safe, effective, all-oral HCV regimens. In a phase 2 study we aimed to assess the efficacy and safety of grazoprevir (MK-5172; HCV NS3/4A protease inhibitor) and two doses of elbasvir (MK-8742; HCV NS5A inhibitor) in patients with HCV mono-infection and HIV/HCV co-infection. |
X Demographics
The data shown below were collected from the profiles of 13 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United Kingdom | 2 | 15% |
| France | 1 | 8% |
| Canada | 1 | 8% |
| Spain | 1 | 8% |
| Japan | 1 | 8% |
| Gibraltar | 1 | 8% |
| Germany | 1 | 8% |
| Unknown | 5 | 38% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 11 | 85% |
| Practitioners (doctors, other healthcare professionals) | 2 | 15% |
Mendeley readers
The data shown below were compiled from readership statistics for 180 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Japan | 1 | <1% |
| Italy | 1 | <1% |
| France | 1 | <1% |
| Unknown | 177 | 98% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 29 | 16% |
| Student > Ph. D. Student | 25 | 14% |
| Other | 23 | 13% |
| Student > Master | 18 | 10% |
| Student > Bachelor | 16 | 9% |
| Other | 36 | 20% |
| Unknown | 33 | 18% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 85 | 47% |
| Agricultural and Biological Sciences | 10 | 6% |
| Immunology and Microbiology | 8 | 4% |
| Nursing and Health Professions | 6 | 3% |
| Pharmacology, Toxicology and Pharmaceutical Science | 5 | 3% |
| Other | 25 | 14% |
| Unknown | 41 | 23% |
Attention Score in Context
This research output has an Altmetric Attention Score of 53. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 07 September 2018.
All research outputs
#802,811
of 25,374,647 outputs
Outputs from The Lancet
#6,605
of 42,669 outputs
Outputs of similar age
#8,767
of 271,257 outputs
Outputs of similar age from The Lancet
#119
of 524 outputs
Altmetric has tracked 25,374,647 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 96th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 42,669 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 67.9. This one has done well, scoring higher than 84% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 271,257 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 96% of its contemporaries.
We're also able to compare this research output to 524 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 77% of its contemporaries.